MarketWatch: Market access for biopharmaceuticals: New challenges

Health Affairs

Volumn 25, Issue 5, 2006, Pages 1363-1370

  Simon, Françoise ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOTECHNOLOGY; DRUG APPROVAL; DRUG INDUSTRY; ECONOMICS; HEALTH CARE DELIVERY; HUMAN; PHARMACEUTICS; UNITED STATES;

BIOPHARMACEUTICS; BIOTECHNOLOGY; DRUG APPROVAL; DRUG INDUSTRY; HEALTH SERVICES ACCESSIBILITY; HUMANS; UNITED STATES;

EID: 33749422081     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.25.5.1363     Document Type: Review

References (35)

1. E. Licking et al., "Reviewing 2005 and Previewing 2006: The Top Stories," In Vivo (January 2006): 45-52;
2. and IMS Health, IMS Market Prognosis 2005 (Fairfield, Conn.: IMS Health, 2005).
3. Tufts Center for the Study of Drug Development, Outlook 2001 (Boston: Tufts University, 2001),
4. as reported in J.D. Kleinke, "The Price of Progress: Prescription Drugs in the Health Care Market," Health Affairs 20, no. 5 (2001): 43-60.
5. See also F.R. Lichtenberg, "Are the Benefits of Newer Drugs Worth Their Cost? Evidence from the 1996 MEPS," Health Affairs 20, no. 5 (2001): 241-251.
6. J.D. Kleinke, "Access versus Excess: Value-based Cost Sharing for Prescription Drugs," Health Affairs 23 (2004): w546-w560 (published online 8 December 2004); 10.1377/hlthaff.w4.546).
7. F. Simon and P. Kotler, Building Global Biobrands: Taking Biotechnology to Market (New York: Free Press, 2003);
8. see chapters "Balancing Access and Price," 207-228;
9. and "Biopricing Strategies," 229-255.
10. J.A. Vernon et al., "Economic and Developmental Considerations for Pharmacogenomic Technology," PharmacoEconomics 24, no. 4 (2006): 335-343.
11. See also A. Salvado et al., "Biotechnology and Managed Care," Journal of Managed Care Pharmacy 6, no. 5 (2000): 410-414.
12. Simon and Kotler, Building Global Biobrands, 106-108, 257-263.
13. J. Hjelmgren, F. Berggren, and F. Andersson, "Health Economic Guidelines - Similarities, Differences, and Some Implications," Value in Health 4, no. 3 (2001): 225-250.
14. See also M.F. van Oostenbruggen et al., "Penny and Pound Wise: Pharmacoeconomics from a Governmental Perspective," PharmacoEconomics 23, no. 3 (2005): 219-226;
15. and Academy of Managed Care Pharmacy, "The AMCP Format for Formulary Submissions, Version 2.1," Journal of Managed Care Pharmacy 11, no. 5, Supp. S-b (2005), http://www.amcp.org/data/jmcp/formatsupp.pdf (accessed 28 June 2006).
16. Food and Drug Administration, "Guidance for Industry: Patient-reported Outcomes Measures," Draft Guidance, February 2006, http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0044-gdl0001.pdf (accessed 16 June 2006).
17. M. Lubkeman et al., "How Biopharma Can Flourish in a Deteriorating Environment," In Vivo (January 2006): 60-67.
18. D. Hughes, "Rationing of Drugs for Rare Diseases," PharmacoEconomics 24, no. 4 (2006): 315-316.
19. S. Calabro, " The Price of Success," Pharmaceutical Executive (March 2006): 65-80.
20. S. Calabro, " The Price of Success," Pharmaceutical Executive (2006): 65-80.Ibid.
21. S. Calabro, " The Price of Success," Pharmaceutical Executive (2006): 65-80.Ibid.
22. Amgen, Amgen Annual Report (Thousand Oaks, Calif.: Amgen, 2005);
23. and "What's a Drug Worth to Medicare?" MedAdNews 22, no. 12 (2003): 6, 53.
24. What's a Drug Worth to Medicare?" MedAdNews 22, no. 12 (2003): 6, Ibid.
25. What's a Drug Worth to Medicare?" MedAdNews 22, no. 2003): 6, Ibid.
26. What's a Drug Worth to Medicare?" MedAdNews 22, no. 2003): 6, Ibid.
27. R. Bonte-Friedheim et al., "The Multiple Sclerosis Wars," Citigroup/Smith Barney Report (New York and London: Citigroup/Smith Barney, 1 December 2004);
28. Biogen Idec, Financial Reports (Cambridge, Mass.: Biogen, 2005); and Schering AG (Berlin: Schering, 2005).
29. Financial Reports 2005); Ibid.
30. Financial Reports 2005); Ibid.
31. H. Dawson, "Promoting Me-Too Biologicals: Portfolio versus Single Product Approach," In Vivo (September 2004): 83-85;
32. and N. D'Amore, "Non-Injectable Insulin Approved," MedAdNews 25, no. 3 (2006): 78.
33. N. D'Amore, "Non-Injectable Insulin Approved," MedAdNews 25, no. 3 78.Ibid.
34. Simon and Kotler, Building Global Biobrands, 232-239.
35. U.E. Reinhardt, "Perspectives on the Pharmaceutical Industry," Health Affairs 20, no. 5 (2001): 136-149.